{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:13:57Z","timestamp":1762506837761,"version":"3.37.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["R01 LM011369"],"award-info":[{"award-number":["R01 LM011369"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Identification of associations between marketed drugs and adverse events from the biomedical literature assists drug safety monitoring efforts. Assessing the significance of such literature-derived associations and determining the granularity at which they should be captured remains a challenge. Here, we assess how defining a selection of adverse event terms from MeSH, based on information content, can improve the detection of adverse events for drugs and drug classes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyze a set of 105,354 candidate drug adverse event pairs extracted from article indexes in MEDLINE. First, we harmonize extracted adverse event terms by aggregating them into higher-level MeSH terms based on the terms\u2019 information content. Then, we determine statistical enrichment of adverse events associated with drug and drug classes using a conditional hypergeometric test that adjusts for dependencies among associated terms. We compare our results with methods based on disproportionality analysis (proportional reporting ratio, PRR) and quantify the improvement in signal detection with our generalized enrichment analysis (GEA) approach using a gold standard of drug-adverse event associations spanning 174 drugs and four events. For single drugs, the best GEA method (Precision: .92\/Recall: .71\/F1-measure: .80) outperforms the best PRR based method (.69\/.69\/.69) on all four adverse event outcomes in our gold standard. For drug classes, our GEA performs similarly (.85\/.69\/.74) when increasing the level of abstraction for adverse event terms. Finally, on examining the 1609 individual drugs in our MEDLINE set, which map to chemical substances in ATC, we find signals for 1379 drugs (10,122 unique adverse event associations) on applying GEA with <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We present an approach based on generalized enrichment analysis that can be used to detect associations between drugs, drug classes and adverse events at a given level of granularity, at the same time correcting for known dependencies among events. Our study demonstrates the use of GEA, and the importance of choosing appropriate abstraction levels to complement current drug safety methods. We provide an R package for exploration of alternative abstraction levels of adverse event terms based on information content.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-016-1080-z","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T04:55:47Z","timestamp":1466744147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature"],"prefix":"10.1186","volume":"17","author":[{"given":"Rainer","family":"Winnenburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigam H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1086-5802(16)31229-3","volume":"41","author":"FR Ernst","year":"2001","unstructured":"Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192\u20139.","journal-title":"J Am Pharm Assoc"},{"key":"1080_CR2","unstructured":"The HCUP Nationwide Emergency Department Sample (NEDS), 2012 [Internet]. [cited 2015 Sep 18]. Available from: http:\/\/www.hcup-us.ahrq.gov\/db\/nation\/neds\/NEDS_Introduction_2012.jsp."},{"key":"1080_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1745-6215-13-138","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138.","journal-title":"Trials"},{"key":"1080_CR4","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0976-500X.120957","volume":"4","author":"J Sultana","year":"2013","unstructured":"Sultana J, Cutroneo P, Trifir\u00f2 G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:S73\u20137.","journal-title":"J Pharmacol Pharmacother"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"e3645","DOI":"10.1136\/bmj.e3645","volume":"344","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case\u2013control study. BMJ. 2012;344:e3645.","journal-title":"BMJ"},{"key":"1080_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhang Y (D), Zhao P, Huang S-M. Predicting drug\u2013drug interactions: an FDA perspective. AAPS J. 2009;11:300\u20136.","journal-title":"AAPS J"},{"key":"1080_CR7","unstructured":"FDA Adverse Event Reporting System (FAERS) [Internet]. Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm."},{"key":"1080_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1080_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1517\/14740338.6.4.451","volume":"6","author":"RP van Manen","year":"2007","unstructured":"van Manen RP, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf. 2007;6:451\u201364.","journal-title":"Expert Opin Drug Saf"},{"key":"1080_CR10","doi-asserted-by":"publisher","first-page":"i133","DOI":"10.1007\/BF02416926","volume":"80","author":"A Szarfman","year":"2003","unstructured":"Szarfman A. Syndromic surveillance and risk management using multiitem gamma poisson shrinker. J Urban Health Bull N Y Acad Med. 2003;80:i133.","journal-title":"J Urban Health Bull N Y Acad Med"},{"key":"1080_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1080_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1055\/s-0032-1328890","volume":"38","author":"TJ Moore","year":"2012","unstructured":"Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:905\u20137.","journal-title":"Semin Thromb Hemost"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2012","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2012;29:385\u201396.","journal-title":"Drug Saf"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1197\/jamia.M3028","volume":"16","author":"X Wang","year":"2009","unstructured":"Wang X, Hripcsak G, Markatou M, Friedman C. Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. J Am Med Inform Assoc JAMIA. 2009;16:328\u201337.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.1926","volume":"19","author":"S Schneeweiss","year":"2010","unstructured":"Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858\u201368.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 9","key":"1080_CR16","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2105-11-S9-S7","volume":"11","author":"R Harpaz","year":"2010","unstructured":"Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010;11 Suppl 9:S7.","journal-title":"BMC Bioinformatics"},{"key":"1080_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1185\/03007990902820519","volume":"25","author":"DD Dore","year":"2009","unstructured":"Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019\u201327.","journal-title":"Curr Med Res Opin"},{"key":"1080_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jamia.2010.008607","volume":"17","author":"PM Nadkarni","year":"2010","unstructured":"Nadkarni PM. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J Am Med Inform Assoc JAMIA. 2010;17:671\u20134.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"1080_CR19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jamia\/ocu041","volume":"22","author":"A Nikfarjam","year":"2015","unstructured":"Nikfarjam A, Sarker A, O\u2019Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22:671\u201381.","journal-title":"J Am Med Inform Assoc"},{"key":"1080_CR20","first-page":"112","volume":"2013","author":"Z Luo","year":"2013","unstructured":"Luo Z, Zhang G-Q, Xu R. Mining patterns of adverse events using aggregated clinical trial results. AMIA Summits Transl Sci Proc. 2013;2013:112\u20136.","journal-title":"AMIA Summits Transl Sci Proc"},{"key":"1080_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13326-015-0017-1","volume":"6","author":"R Winnenburg","year":"2015","unstructured":"Winnenburg R, Sorbello A, Bodenreider O. Exploring adverse drug events at the class level. J Biomed Semant. 2015;6:18.","journal-title":"J Biomed Semant"},{"key":"1080_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/amiajnl-2011-000096","volume":"18","author":"KD Shetty","year":"2011","unstructured":"Shetty KD, Dalal SR. Using information mining of the medical literature to improve drug safety. J Am Med Inform Assoc JAMIA. 2011;18:668\u201374.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"1080_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs Drugs Devices Interv. 2008;8:373\u2013418.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"1080_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/amiajnl-2013-001612","volume":"21","author":"SV Iyer","year":"2014","unstructured":"Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc JAMIA. 2014;21:353\u201362.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"1080_CR25","doi-asserted-by":"publisher","first-page":"i547","DOI":"10.1093\/bioinformatics\/btq382","volume":"26","author":"L Tari","year":"2010","unstructured":"Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinforma Oxf Engl. 2010;26:i547\u201353.","journal-title":"Bioinforma Oxf Engl"},{"key":"1080_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"1080_CR27","doi-asserted-by":"publisher","first-page":"D1049","DOI":"10.1093\/nar\/gku1179","volume":"43","author":"TGO Consortium","year":"2015","unstructured":"Consortium TGO. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43:D1049\u201356.","journal-title":"Nucleic Acids Res"},{"key":"1080_CR28","doi-asserted-by":"publisher","first-page":"R28","DOI":"10.1186\/gb-2003-4-4-r28","volume":"4","author":"BR Zeeberg","year":"2003","unstructured":"Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol. 2003;4:R28.","journal-title":"Genome Biol"},{"key":"1080_CR29","first-page":"279","volume":"121","author":"K Donnelly","year":"2006","unstructured":"Donnelly K. SNOMED-CT: The advanced terminology and coding system for eHealth. Stud Health Technol Inform. 2006;121:279\u201390.","journal-title":"Stud Health Technol Inform"},{"key":"1080_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/humu.21192","volume":"31","author":"M Mort","year":"2010","unstructured":"Mort M, Evani US, Krishnan VG, Kamati KK, Baenziger PH, Bagchi A, et al. In silico functional profiling of human disease-associated and polymorphic amino acid substitutions. Hum Mutat. 2010;31:335\u201346.","journal-title":"Hum Mutat"},{"key":"1080_CR31","first-page":"797","volume":"2010","author":"R Tirrell","year":"2010","unstructured":"Tirrell R, Evani U, Berman AE, Mooney SD, Musen MA, Shah NH. An ontology-neutral framework for enrichment analysis. AMIA Annu Symp Proc. 2010;2010:797\u2013801.","journal-title":"AMIA Annu Symp Proc"},{"key":"1080_CR32","doi-asserted-by":"publisher","first-page":"e1002827","DOI":"10.1371\/journal.pcbi.1002827","volume":"8","author":"NH Shah","year":"2012","unstructured":"Shah NH, Cole T, Musen MA. Chapter 9: analyses using disease ontologies. PLoS Comput Biol. 2012;8:e1002827.","journal-title":"PLoS Comput Biol"},{"key":"1080_CR33","first-page":"2412","volume":"33","author":"K Michaud","year":"2006","unstructured":"Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. J Rheumatol. 2006;33:2412\u20135.","journal-title":"J Rheumatol"},{"key":"1080_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S2453","volume":"4","author":"C Turesson","year":"2008","unstructured":"Turesson C, Jacobsson LTH, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008;4:605\u201314.","journal-title":"Vasc Health Risk Manag"},{"key":"1080_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.berh.2008.11.007","volume":"23","author":"H John","year":"2009","unstructured":"John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23:71\u201382.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1080_CR36","doi-asserted-by":"publisher","first-page":"D322","DOI":"10.1093\/nar\/gkl799","volume":"35","author":"G Alterovitz","year":"2007","unstructured":"Alterovitz G, Xiang M, Mohan M, Ramoni MF. GO PaD: the gene ontology partition database. Nucleic Acids Res. 2007;35:D322\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1080_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2041-1480-3-15","volume":"3","author":"H Gurulingappa","year":"2012","unstructured":"Gurulingappa H, Mateen\u2010Rajput A, Toldo L. Extraction of potential adverse drug events from medical case reports. J Biomed Semantics. 2012;3:15.","journal-title":"J Biomed Semantics"},{"key":"1080_CR38","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/jamia\/ocv102","volume":"22","author":"G Wang","year":"2015","unstructured":"Wang G, Jung K, Winnenburg R, Shah NH. A method for systematic discovery of adverse drug events from clinical notes. J Am Med Inform Assoc. 2015;22:1196\u2013204.","journal-title":"J Am Med Inform Assoc"},{"key":"1080_CR39","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/amiajnl-2012-001083","volume":"20","author":"P Avillach","year":"2013","unstructured":"Avillach P, Dufour J-C, Diallo G, Salvo F, Joubert M, Thiessard F, et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. J Am Med Inform Assoc JAMIA. 2013;20:446\u201352.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"1080_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jbi.2015.08.022","volume":"57","author":"R Winnenburg","year":"2015","unstructured":"Winnenburg R, Sorbello A, Ripple A, Harpaz R, Tonning J, Szarfman A, et al. Leveraging MEDLINE indexing for pharmacovigilance \u2013 Inherent limitations and mitigation strategies. J Biomed Inform. 2015;57:425\u201335.","journal-title":"J Biomed Inform"},{"key":"1080_CR41","unstructured":"RxNorm [Internet]. [cited 2015 Sep 29]. Available from: https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm\/."},{"key":"1080_CR42","unstructured":"WHOCC - ATC\/DDD Index [Internet]. [cited 2015 Sep 29]. Available from: http:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"1080_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","volume":"27","author":"CE Shannon","year":"1948","unstructured":"Shannon CE. A mathematical theory of communication. Bell Syst Tech J. 1948;27:379\u2013423.","journal-title":"Bell Syst Tech J"},{"key":"1080_CR44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"1080_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/11534410-000000000-00000","volume":"33","author":"Y Alvarez","year":"2010","unstructured":"Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33:475\u201387.","journal-title":"Drug Saf"},{"key":"1080_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1080_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623\u20135.","journal-title":"Drug Saf"},{"key":"1080_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12859-015-0453-z","volume":"16","author":"K Tsuyuzaki","year":"2015","unstructured":"Tsuyuzaki K, Morota G, Ishii M, Nakazato T, Miyazaki S, Nikaido I. MeSH ORA framework: R\/Bioconductor packages to support MeSH over-representation analysis. BMC Bioinformatics. 2015;16:45.","journal-title":"BMC Bioinformatics"},{"key":"1080_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, Wang L-G, Yan G-R, He Q-Y. DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31:608\u20139.","journal-title":"Bioinformatics"},{"key":"1080_CR50","doi-asserted-by":"publisher","first-page":"140032","DOI":"10.1038\/sdata.2014.32","volume":"1","author":"SG Finlayson","year":"2014","unstructured":"Finlayson SG, LePendu P, Shah NH. Building the graph of medicine from millions of clinical narratives. Sci Data. 2014;1:140032.","journal-title":"Sci Data"},{"key":"1080_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-013-0097-8","volume":"36","author":"PB Ryan","year":"2013","unstructured":"Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a Reference Set to Support Methodological Research in drug safety. Drug Saf. 2013;36:33\u201347.","journal-title":"Drug Saf"},{"key":"1080_CR52","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jbi.2012.04.004","volume":"45","author":"EM van Mulligen","year":"2012","unstructured":"van Mulligen EM, Fourrier-Reglat A, Gurwitz D, Molokhia M, Nieto A, Trifiro G, et al. The EU-ADR corpus: annotated drugs, diseases, targets, and their relationships. J Biomed Inform. 2012;45:879\u201384.","journal-title":"J Biomed Inform"},{"key":"1080_CR53","unstructured":"DailyMed - PIOGLITAZONE HYDROCHLORIDE- pioglitazone hydrochloride tablet [Internet]. [cited 2015 Aug 3]. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3&audience=professional."},{"key":"1080_CR54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.taap.2011.01.006","volume":"251","author":"K Sato","year":"2011","unstructured":"Sato K, Awasaki Y, Kandori H, Tanakamaru Z-Y, Nagai H, Baron D, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol. 2011;251:234\u201344.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1080_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, et al. PIoglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265\u201377.","journal-title":"JAMA"},{"key":"1080_CR56","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/jnci\/djs328","volume":"104","author":"R Mamtani","year":"2012","unstructured":"Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012;104:1411\u201321.","journal-title":"J Natl Cancer Inst"},{"key":"1080_CR57","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","volume":"55","author":"A Neumann","year":"2012","unstructured":"Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953\u201362.","journal-title":"Diabetologia"},{"key":"1080_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40261-013-0106-9","volume":"33","author":"C Vallarino","year":"2013","unstructured":"Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 2013;33:621\u201331.","journal-title":"Clin Drug Investig"},{"key":"1080_CR59","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2125.2012.04325.x","volume":"75","author":"L Wei","year":"2013","unstructured":"Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75:254\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1080_CR60","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/dme.12144","volume":"30","author":"M Ferwana","year":"2013","unstructured":"Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med J Br Diabet Assoc. 2013;30:1026\u201332.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"1080_CR61","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2337\/dc10-2412","volume":"34","author":"C Piccinni","year":"2011","unstructured":"Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369\u201371.","journal-title":"Diabetes Care"},{"key":"1080_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.diabres.2012.05.006","volume":"98","author":"Z Zhu","year":"2012","unstructured":"Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98:159\u201363.","journal-title":"Diabetes Res Clin Pract"},{"key":"1080_CR63","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.diabres.2012.11.013","volume":"99","author":"K Fujimoto","year":"2013","unstructured":"Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99:e21\u20133.","journal-title":"Diabetes Res Clin Pract"},{"key":"1080_CR64","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40264-014-0198-z","volume":"37","author":"GN Nor\u00e9n","year":"2014","unstructured":"Nor\u00e9n GN, Caster O, Juhlin K, Lindquist M. Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. Drug Saf. 2014;37:655\u20139.","journal-title":"Drug Saf"},{"key":"1080_CR65","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539\u201346.","journal-title":"Clin Pharmacol Ther"},{"key":"1080_CR66","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jfms.2011.06.008","volume":"13","author":"RA Gowan","year":"2011","unstructured":"Gowan RA, Lingard AE, Johnston L, Stansen W, Brown SA, Malik R. Retrospective case\u2013control study of the effects of long-term dosing with meloxicam on renal function in aged cats with degenerative joint disease. J Feline Med Surg. 2011;13:752\u201361.","journal-title":"J Feline Med Surg"},{"key":"1080_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1385\/MO:19:2:117","volume":"19","author":"MR Altiparmak","year":"2002","unstructured":"Altiparmak MR, Bilici A, Kisacik B, Ozguroglu M. Flutamide-induced acute renal failure in a patient with metastatic prostate cancer. Med Oncol Northwood Lond Engl. 2002;19:117\u20139.","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"1080_CR68","first-page":"250","volume":"18","author":"G Famularo","year":"2003","unstructured":"Famularo G, De Simone C, Minisola G, Nicotra GC. Flutamide-associated acute liver failure. Ann Ital Med Int Organo Uff Della Soc Ital Med Interna. 2003;18:250\u20133.","journal-title":"Ann Ital Med Int Organo Uff Della Soc Ital Med Interna"},{"key":"1080_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/00000421-199708000-00024","volume":"20","author":"A Smith","year":"1997","unstructured":"Smith A, Harbour D, Liebmann J. Acute renal failure in a patient receiving treatment with suramin. Am J Clin Oncol. 1997;20:433\u20134.","journal-title":"Am J Clin Oncol"},{"key":"1080_CR70","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/archinternmed.2011.103","volume":"171","author":"MA Weir","year":"2011","unstructured":"Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med. 2011;171:703\u20134.","journal-title":"Arch Intern Med"},{"key":"1080_CR71","unstructured":"DailyMed - XENICAL- orlistat capsule [Internet]. [cited 2015 Aug 6]. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=5bbdc95b-82a1-4ba5-8185-6504ff68cc06."},{"key":"1080_CR72","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40264-014-0245-9","volume":"38","author":"R Harpaz","year":"2015","unstructured":"Harpaz R, DuMouchel W, Shah NH. Comment on: \u201cZoo or savannah? Choice of training ground for evidence-based pharmacovigilance.\u201d. Drug Saf. 2015;38:113\u20134.","journal-title":"Drug Saf"},{"key":"1080_CR73","doi-asserted-by":"publisher","first-page":"140043","DOI":"10.1038\/sdata.2014.43","volume":"1","author":"R Harpaz","year":"2014","unstructured":"Harpaz R, Odgers D, Gaskin G, DuMouchel W, Winnenburg R, Bodenreider O, et al. A time-indexed reference standard of adverse drug reactions. Sci Data. 2014;1:140043.","journal-title":"Sci Data"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1080-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-016-1080-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1080-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1080-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T18:03:20Z","timestamp":1706810600000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-016-1080-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1186\/s12859-016-1080-z","relation":{},"ISSN":["1471-2105"],"issn-type":[{"type":"electronic","value":"1471-2105"}],"subject":[],"published":{"date-parts":[[2016,6,23]]},"assertion":[{"value":"30 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"250"}}